Gynecologic Oncology Reports Oncology

Real-world outcomes after Mirvetuximab Soravtansine treatment for recurrent ovarian Cancer: Results from a university setting

Elsevier ·

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →